Does Saudi ANKTIVA Launch Signal a New Phase in ImmunityBio's (IBRX) Commercial Strategy? [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
indications, with distribution supported by regional partners Biopharma and Cigalah Healthcare and its local subsidiary. This marks one of the first commercial rollouts of ANKTIVA for both bladder and lung cancer in the Middle East and North Africa, a region facing a rapidly growing cancer burden and rising demand for additional treatment options. We'll now examine how ANKTIVA's commercial launch in Saudi Arabia, including its lung cancer indication, could influence ImmunityBio's investment narrative. Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge ImmunityBio Investment Narrative Recap To own ImmunityBio, you need to believe ANKTIVA can move from a single core bladder cancer product toward a broader global franchise, including lung cancer. The Saudi launch adds another real world test of that thesis, but the key near term catalyst remains regulatory and commercial progress in larger markets, while the biggest risk is that ANKTIVA upt
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitGlobeNewswire
- ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCPR Newswire
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The Firm - IBRXACCESS Newswire
- Pomerantz LLP Notifies Investors of Class Action Against ImmunityBio, Inc. – IBRXACCESS Newswire
- ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitPR Newswire
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 4/9/26 - Form 8-K
- 4/6/26 - Form 8-K
- 4/2/26 - Form 4
- IBRX's page on the SEC website